ONCOTELIC ACQUIRES FAST TO MARKET LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.
04 oct. 2021 07h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), executed an exclusive licensing agreement on September 30, 2021,...